熱門資訊> 正文
Klotho Neurosciences将收购Turn Biotechnologies的精选资产
2025-09-30 21:25
- Klotho Neurosciences (NASDAQ:KLTO) said on Tuesday that it has signed a Letter of Intent (LOI) to acquire select assets from Turn Biotechnologies.
- Under the LOI, Klotho would acquire Turn's ERA ("Epigenetic Reprogramming of Age") platform and eTurna RNA delivery system.
- Importantly, as part of this transaction, Klotho will be acquiring a signed out-licensing and co-development partnership with one of South Korea's leading pharmaceutical companies worth up to $300 million.
More on Klotho Neurosciences, Inc.
- Financial information for Klotho Neurosciences, Inc.
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
